| abstract |
Use of a compound of formula (I): wherein n is 0, 1 or 2; R is hydroxyl, metoxy, C1-7 alkanoyloxy, C3-7 cycloalkanoyloxy, C1-6 alkoxy C1-7-alkanoyloxy, an aroyloxy group, wherein aryl portion is selected from the set of phenyl, naphthyl, thienyl and furyl. The aryl portion is monosubstituted by a group from the hydroxyl set, halogen, C1-3 alkyl and C1-3 alkoxy or it represents aryloxycarbonyloxy, wherein aryl portion is selected from the set of phenyl, naphthyl, thienyl and furyl. The aryl portion is monosubstituted by a group from the hydroxyl set, halogen, C1-3 alkyl and C1-3 alkoxy, R1 is hydrogen, hydroxyl, halogen, metoxy, C1-7 alkanoyloxy, C3-7 cycloalkanoyloxy, C1-6 alkoxy C1-7 alkanoyloxy, an aroyloxy group, wherein aryl portion is selected from the set of phenyl, naphthyl, thienyl and furyl. The aryl portion is monosubstituted by a group from the hydroxyl set, halogen, C1-3 alkyl and C1-3 alkoxy or it represents an aryloxycarbonyloxy group, wherein aryl portion is selected from the set of phenyl, naphthyl, thienyl and furyl. The aryl portion is monosubstituted by the hydroxyl set, halogen, C1-3 alkyl and C1-3 alkoxy, R2 is a heterocyclic group selected from the set containing a pyrrolidino, piperidino and hexamethyleneimino group; or a pharmaceutically acceptable salt or solvate thereof; in the preparation of a medicament useful for lowering serum cholesterol levels in humans. |